dc.contributor.author |
Jermendy G |
|
dc.contributor.author |
Kiss Z |
|
dc.contributor.author |
Rokszin G |
|
dc.contributor.author |
Abonyi-Toth, Zsolt |
|
dc.contributor.author |
Wittmann, István |
|
dc.contributor.author |
Kempler, Péter |
|
dc.date.accessioned |
2019-06-03T11:52:24Z |
|
dc.date.available |
2019-06-03T11:52:24Z |
|
dc.date.issued |
2018 |
|
dc.identifier |
85054124061 |
|
dc.identifier.citation |
journalVolume=9;journalIssueNumber=5;journalTitle=DIABETES THERAPY;pagerange=2133-2141;journalAbbreviatedTitle=DIABTHERAP; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/7047 |
|
dc.identifier.uri |
doi:10.1007/s13300-018-0483-4 |
|
dc.description.abstract |
INTRODUCTION: Adequate persistence to antidiabetic treatment is highly important to achieve proper glycemic control. In this study we evaluate the persistence to treatment with dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists in a nationwide cohort of patients with type 2 diabetes. METHODS: Using a central database in Hungary, we analyzed the persistence to the treatment with dipeptidyl peptidase-4 inhibitors (n = 59,900), sodium-glucose co-transporter-2 inhibitors (n = 26,052), and glucagon-like peptide-1 receptor agonists (n = 17,332) at treatment intensification between 2014 and 2016. We also compared the persistence of dipeptidyl peptidase-4 inhibitors (n = 9163) and sodium-glucose co-transporter-2 inhibitors (n = 1257) in initial therapy to that of metformin (n = 79,305) or sulfonylureas (n = 29,057). The rates of persistence to treatment and risk of non-persistence are reported. RESULTS: The persistence rates of dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists at treatment intensification were 69.6%, 67.8%, and 66.3% at year 1 which decreased to 57.3%, 56.8%, and 52.1% by year 2, respectively. The risk of non-persistence was higher by 6.6% (95% CI 3.6-9.6) for sodium-glucose co-transporter-2 inhibitors and by 8.3% (95% CI 5.0-11.5) for glucagon-like peptide-1 receptor agonists as compared to dipeptidyl peptidase-4 inhibitors. Novel oral antidiabetic drugs in fixed versus free add-on combinations with metformin had higher persistence. The persistence to treatment with novel oral antidiabetic drugs in initial therapy was better (dipeptidyl peptidase-4 inhibitors, 59.6% and 47.6%; sodium-glucose co-transporter-2 inhibitors, 61.9% and 47.0%) than that of initial monotherapy with metformin (47.0% and 39.1%) or sulfonylureas (52.4% and 41.8%) at years 1 and 2, respectively. CONCLUSION: Analysis of persistence of treatment with novel glucose-lowering medications revealed differences between drug classes, favoring dipeptidyl peptidase-4 inhibitors vs. sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Persistence data of novel antihyperglycemic agents may be useful for guiding the decision at initiation of antidiabetic treatment. FUNDING: Hungarian Diabetes Association. Plain language summary available for this article. |
|
dc.format.extent |
2133-2141 |
|
dc.title |
Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes |
|
dc.type |
Journal Article |
|
dc.date.updated |
2019-06-03T11:34:58Z |
|
dc.language.rfc3066 |
en |
|
dc.rights.holder |
NULL |
|
dc.identifier.mtmt |
3407189 |
|
dc.identifier.wos |
000446637300033 |
|
dc.identifier.pubmed |
30120754 |
|
dc.contributor.institution |
Biomatematikai és számítástechnikai tanszék |
|
dc.contributor.institution |
II.sz. Belgyógyászati Klinika és Nephrológiai Centrum |
|
dc.contributor.institution |
Biomatematikai és számítástechnikai tanszék |
|
dc.contributor.institution |
Biomatematikai és számítástechnikai tanszék |
|
dc.contributor.institution |
I. Sz. Belgyógyászati Klinika |
|